RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Apremilastin Patients with Psoriatic Arthritis: Results of the PALACE-1 Trial
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 19
SP 19
OP 19
DO 10.1177/155989771219016
UL http://mdc.sagepub.com/content/12/19/19.abstract
AB In PALACE-1 trial apremilast, an oral phosphodiesterase 4 inhibitor, was shown to be safe and effective in treating psoriatic arthritis (PsA) in subjects previously exposed to disease-modifying antirheumatic drugs. Apremilast modulates the production of pro- (tumor necrosis factor-a, natural killer cells, and epidermal keratinocytes) and anti-inflammatory mediators (interleukin-10), including those implicated in the etiopathogenesis of PsA.